J
John W. Babich
Researcher at Cornell University
Publications - 335
Citations - 11566
John W. Babich is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 54, co-authored 331 publications receiving 10570 citations. Previous affiliations of John W. Babich include The Royal Marsden NHS Foundation Trust & Brigham and Women's Hospital.
Papers
More filters
Journal Article
The Dose Uptake Ratio as an Index of Glucose Metabolism: Useful Parameter or Oversimplification?
Leena Hamberg,George J. Hunter,Nathaniel M. Alpert,Noah C. Choi,John W. Babich,Alan J. Fischman +5 more
TL;DR: DUR can vary widely with the time of measurement and that DUR should be interpreted with caution in any individual patient, according to the data investigated.
Journal ArticleDOI
Radiation dosimetry and first therapy results with a 124I/131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy
Christian M. Zechmann,Ali Afshar-Oromieh,Tom Armor,James B. Stubbs,Walter Mier,Boris Hadaschik,John Joyal,Klaus Kopka,Jürgen Debus,John W. Babich,Uwe Haberkorn +10 more
TL;DR: Tissue kinetics of a small molecule inhibitor of PSMA using PET/CT to estimate radiation dosimetry for the potential therapeutic use of 131I-MIP-1095 in men with mCRPC enables a targeted tumor therapy with unprecedented doses delivered to the tumor lesions.
Journal ArticleDOI
Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.
Shawn Hillier,Kevin P. Maresca,Frank J. Femia,John C. Marquis,Catherine A. Foss,Nghi Nguyen,Craig Zimmerman,John A. Barrett,William C. Eckelman,Martin G. Pomper,John Joyal,John W. Babich +11 more
TL;DR: Specific binding to PSMA in vivo was shown by competition with PMPA in LNCaP xenografts, and the absence of uptake in PC3 xenografteds.
Journal ArticleDOI
A series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer.
Kevin P. Maresca,Shawn Hillier,Frank J. Femia,D. Keith,C. Barone,John Joyal,Craig Zimmerman,Alan P. Kozikowski,John A. Barrett,William C. Eckelman,John W. Babich +10 more
TL;DR: Two lead iodine compounds were radiolabeled with (123)I and (131)Iand demonstrated specific PSMA binding on human prostate cancer cells, warranting evaluation as radioligands for the detection, staging, and monitoring of prostate cancer.
Journal ArticleDOI
Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer
Ying Chen,Catherine A. Foss,Youngjoo Byun,Sridhar Nimmagadda,Mrudula Pullambhatla,James Fox,Mark Castanares,Shawn E. Lupold,John W. Babich,Ronnie C. Mease,Martin G. Pomper +10 more
TL;DR: The versatile intermediate 2-[3-(5-amino-1-carboxy-pentyl)-ureido]-pentanedioic acid (Lys-C(O)-Glu) is used to extend the development of new imaging agents targeting the prostate-specific membrane antigen (PSMA) with clear delineation of the tumor by SPECT.